Isotretinoin, Contraception, and Pregnancy Outcomes

Isotretinoin, Contraception, and Pregnancy Outcomes

Isotretinoin, Contraception, and Pregnancy Outcomes

OS0015

Overview

Background
  • Isotretinoin is commonly used in the treatment of severe acne.
  • However, it is known to cause birth defects. To minimize this risk, the pregnancy prevention program in Canada requires the simultaneous use of two methods of contraception during isotretinoin therapy, among other safeguards.
  • Findings from our previous study suggest suboptimal adherence to, or implementation of, the pregnancy prevention program.
Objectives
  • The main objective is to update our previous study to examine the frequency and change in frequency over time of contraception use, pregnancy occurrence, and pregnancy outcomes in individuals of childbearing age prescribed isotretinoin from 1997 to present.

Manuscripts

Presentations

Project Team

Project Co-Lead
Colin R. Dormuth ScD
Project Co-Lead
Greg Carney BSc, PhD
Methods Lead
Karine Suissa
Content Expert
Jonathan Zipursky
Content Expert
Brandace Winquist
Lead Analyst
Tarita Miller BSc
Research Assistant
Audray St-Jean MSc
Site Investigator
Donica Janzen PhD
Saskatchewan
Site Investigator
John-Michael Gamble BSc (Pharm), MSc, PhD
Ontario
Site Investigator
Sherif Eltonsy MSc, PhD
Manitoba
Site Investigator
Greg Carney BSc, PhD
British Columbia
Site Investigator
Paul Ronksley PhD
Alberta
Analyst
Xinya Lu PhD
Saskatchewan
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Tarita Miller BSc
British Columbia